Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia
Susan F. Sonnenschein, Felipe V. Gomes, Anthony A. Grace
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 105

Showing 1-25 of 105 citing articles:

Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment
Masataka Wada, Yoshihiro Noda, Yusuke Iwata, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 7, pp. 2950-2967
Closed Access | Times Cited: 74
The Formation and Function of the VTA Dopamine System
Guoqiang Hou, Hao Mei, Jiawen Duan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3875-3875
Open Access | Times Cited: 16
ADHD: Reviewing the Causes and Evaluating Solutions
Luis Núñez-Jaramillo, Andrea Herrera-Solís, Wendy Verónica Herrera-Morales
Journal of Personalized Medicine (2021) Vol. 11, Iss. 3, pp. 166-166
Open Access | Times Cited: 66
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic
Samantha E. Yohn, Peter J. Weiden, Christian C. Felder, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 12, pp. 1098-1112
Open Access | Times Cited: 60
Schizophrenia: The new etiological synthesis
Markus J. Rantala, Severi Luoto, Javier I. Borráz-León, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 142, pp. 104894-104894
Open Access | Times Cited: 47
The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia
Daniela L. Uliana, João Roberto Lisboa, Felipe V. Gomes, et al.
Biochemical Pharmacology (2024) Vol. 228, pp. 116298-116298
Closed Access | Times Cited: 13
Limbic links to paranoia: increased resting-state functional connectivity between amygdala, hippocampus and orbitofrontal cortex in schizophrenia patients with paranoia
Sebastian Walther, Stéphanie Lefebvre, Frauke Conring, et al.
European Archives of Psychiatry and Clinical Neuroscience (2021) Vol. 272, Iss. 6, pp. 1021-1032
Open Access | Times Cited: 49
The Medial Septum as a Potential Target for Treating Brain Disorders Associated With Oscillopathies
Yuichi Takeuchi, Anett J. Nagy, Lívia Barcsai, et al.
Frontiers in Neural Circuits (2021) Vol. 15
Open Access | Times Cited: 45
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
Felipe V. Gomes, Anthony A. Grace
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4467-4467
Open Access | Times Cited: 44
Inflammation-related transcripts define “high” and “low” subgroups of individuals with schizophrenia and bipolar disorder in the midbrain
Yunting Zhu, Samantha J. Owens, Caitlin E. Murphy, et al.
Brain Behavior and Immunity (2022) Vol. 105, pp. 149-159
Closed Access | Times Cited: 31
Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders
Chad R. Johnson, Brian D. Kangas, Emily M. Jutkiewicz, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 398-398
Open Access | Times Cited: 30
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 17
Prefrontal and Hippocampal Parvalbumin Interneurons in Animal Models for Schizophrenia: A Systematic Review and Meta-analysis
Thamyris Santos‐Silva, Débora dos Santos Fabris, Cilene Lino de Oliveira, et al.
Schizophrenia Bulletin (2023) Vol. 50, Iss. 1, pp. 210-223
Open Access | Times Cited: 16
Frontostriatothalamic effective connectivity and dopaminergic function in the psychosis continuum
Kristina Sabaroedin, Adeel Razi, Sidhant Chopra, et al.
Brain (2022) Vol. 146, Iss. 1, pp. 372-386
Open Access | Times Cited: 26
Effective Action of Silymarin against Ketamine-induced Schizophrenia in Male Mice: Insight into the Biochemical and Molecular Mechanisms of Action
Benneth Ben‐Azu, Aliance Romain Fokoua, Olajide S. Annafi, et al.
Journal of Psychiatric Research (2024) Vol. 179, pp. 141-155
Closed Access | Times Cited: 5
Association between the COX-2 rs689466 polymorphism and antipsychotic treatment: Impact on HDL cholesterol changes in clozapine-treated psychosis patients
Sergej Nadalin, Ivan Ljoka, Aleksandar Savić, et al.
Prostaglandins Leukotrienes and Essential Fatty Acids (2025), pp. 102665-102665
Closed Access
Transcriptional enhancers in human neuronal differentiation provide clues to neuronal disorders
Masahito Yoshihara, Andrea Coschiera, Jörg A. Bachmann, et al.
EMBO Reports (2025)
Closed Access
Batch-fabricated full glassy carbon fibers for real-time tonic and phasic dopamine detection
Umisha Siwakoti, May Yoon Pwint, Austin M. Broussard, et al.
Frontiers in Bioengineering and Biotechnology (2025) Vol. 13
Open Access
The Relationship Between Insomnia and Depressive Symptoms in a Sample of Patients With Schizophrenia: Do Psychotic Symptoms Play a Mediating Role?
Abdallah Abu Khait, Austin Menger, Mohammed Munther Al‐Hammouri, et al.
Journal of Psychiatric and Mental Health Nursing (2025)
Closed Access
Identification of novel amides and alkaloids as putative inhibitors of dopamine transporter for schizophrenia using computer-aided virtual screening
Iqra Ahmad, Anam Tassawer, Muhammad Umer Khan, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
The Development of the Mesoprefrontal Dopaminergic System in Health and Disease
Khondker Ushna Sameen Islam, Norisa Meli, Sandra Blaess
Frontiers in Neural Circuits (2021) Vol. 15
Open Access | Times Cited: 29
Using animal models for the studies of schizophrenia and depression: The value of translational models for treatment and prevention
Daniela L. Uliana, Xiyu Zhu, Felipe V. Gomes, et al.
Frontiers in Behavioral Neuroscience (2022) Vol. 16
Open Access | Times Cited: 21
Subcortical control of the default mode network: Role of the basal forebrain and implications for neuropsychiatric disorders
David D. Aguilar, James M. McNally
Brain Research Bulletin (2022) Vol. 185, pp. 129-139
Open Access | Times Cited: 20
Decrease in gamma-band auditory steady-state response in patients with treatment-resistant schizophrenia
Kamiyu Ogyu, Karin Matsushita, Shiori Honda, et al.
Schizophrenia Research (2023) Vol. 252, pp. 129-137
Open Access | Times Cited: 12
Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets
Anthony A. Grace, Daniela L. Uliana
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12374-12374
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top